Summary: By immunization of mice with the anti-CA 125 monoclonal antibody OC125, we tried to induce antibodies directed against the tumour-associated antigen CA 125, via activation of the idiotypic network. Mice immunized by repeated administrations of F(ab') 2 -fragments of the OC125 antibody produced antiidiotypic antibodies, imitating the original target antigen of the OC125. After induction of these anti-idiotypic antibodies (Ab2ß) a murine IgG-anti-CA 125 (Ab3) response was detected. The induction of idiotypic cascades offers the possibility of immunization against tumour-associated antigens, without using the original antigen and breaking antitumour tolerance.
Introduction
^ . . ,. . ^., , .
u r , type anti-idiotypic antibody has the shape of the Niels Jerne postulated that the immune system con-original antigenic determinant and acts like an intersists of a network of antibodies and lymphocytes nal image of the antigen. The other anti-idiotypic which interact through complementary structures of antibodies are called Ab2a and Ab2y. The Ab2oc recantibodies, anti-antibodies or anti-anti-antibodies (1) . ognizes a non-antigen combining site idiotope someIt is thus proposed that an antigen causes the pro-where on the hypervariable region; the Ab2y recogduction of antibodies (Abl), bearing different idi-nizes an idiotope in close proximity to the antigen otopes characteristic for each antibody clone. These combining site but is not an internal image and may idiotopes can act as antigens and stimulate the pro-be representative of recurrent intrastrain or intraduction of anti-idiotypic antibodies (Ab2), which con-species idiotopes. The Ab2y, like the Ab2ß, recognizes trol the production of Abl, and which in turn are an idiotope within the antigen binding site, but fails controlled by anti-anti-idiotypic antibodies (Ab3).
to exhibit biological mimicry of the antigen. The Ab2ß Within the set of anti-idiotypic antibodies directed f"™*™^ formation of anti-anti-idiotypic antiagainst the several idiotopes of Abl, some bind exbodies (Ab3 >> , which can a 8 ain bind to the P rimar y actly to the antigen binding site. According to the ^ ^ ^ /^ *"* ^ *" ****** ** °* classification originally proposed by Jerne (2) and e '" > < · later modified by Bona & Köhler (3) , these anti-idi-We previously demonstrated the appearance of antiotypic antibodies are designated as AbZß or so called idiotypic antibodies mimicking the tumour-associated internal image anti-idiotype. The idiotope of an Ab2ß antigen CA 125, in ovarian cancer patients after re-peated treatment with F(ab')2-fragments of the anti-CA 125 antibody OC125 (9) . Induction of these antiidiotypic antibodies obviously leads to an improved survival rate, even in advanced stages (10, 11) , by presumably breaking antitumour tolerance. A common explanation for the absence of antitumour immunity is that the immune system has been tolerized by the tumour antigen (12) . An effective method of breaking this tolerance is to present the critical epitope in a different molecular environment to the tolerized host. According to the network hypothesis of Jerne (1), one approach is the transformation of epitope structures into idiotypic determinants expressed on the surface of antibodies.
The aim of this study was to evaluate in an animal model the induction of anti-idiotypic antibodies (Ab2 ), which mimick the tumour-associated antigen CA 125, i. e: to determine whether immunization with F(ab')2-fragments of OC125 antibody subsequently leads to the production of anti-anti-antibodies (Ab3) directed against the target antigen CA 125.
Materials and Methods

Materials
The F(ab') 2 -fragments of the monoclonal antibody OC125 M Ab, which bind to the tumour-associated-antigen CA 125, were generously donated from International CIS, Filiale de Compagnie ORIS Industrie S.A. (Gis-sur-Yvette, France).
The human ovarian adenocarcinoma ceil line OAW42 was supplied by H. L hrke, Deutsches Krebsforschungszentrum (Heidelberg, Germany) and cultured in RPMI medium (Biochrom KG, Berlin. Germany), supplemented with fetal-calf serum (Biochrom KG, Berlin, Germany), volume fraction 0.1, 2 mmol/1 L-glutamine (Boehringer-Mannheim, Mannheim, Germany) and streptomycin/penicillin (Biochrom KG, Berlin, Germany).
Ninety six-well flat bottom Dynatech microtitre plates were obtained from Greiner GmbH & CoKG, N rtingen, Germany. Globulin-free bovine serum albumin, peroxidase-labelled goat anti-mouse-IgG (F c -specific) and peroxidase-labelled goat antimouse-IgM were purchased from Sigma Chemie GmbH (Deisenhofen, Germany) and used without further purification. The peroxidase substrate, o-phenylenediamine, was obtained from Zymed Laboratories Inc., San Francisco, USA. All other chemicals and solvents were obtained from Merck (Darmstadt, Germany) or Aldrich (Steinheim, Germany). 
Purification of CA 125
Culture supernatants of OAW42 celts, containing the CA 125 antigen, were collected after one week of cell growth and stored at -25 °C until use.
Ammonium sulphate fractionaiion
Ammonium sulphate (208 g/1) was added to the culture supernatant. The mixture was centrifuged (10000 g, 20 min) and the precipitate discarded. To the supernatant fraction, 163 g/1 ammonium sulphate was added followed by a second centrifigation. The precipitate was resuspended in buffer A and dialysed overnight against twenty volumes of buffer A.
Gel filtration on Superose 6
0.5 ml of the CA 125-containing ammonium sulphate fraction (35 -60% saturation) was applied to a Superose 6 column (1.5 χ 30 cm, Pharmacia, Freiburg, Germany), equilibrated with buffer A. Fractions containing CA 125 (8 -11 ml elution volume) were pooled and concentrated by Centricon-30 (Amicon, Beverly, USA). Aliquotsofl ml (5000 χ 10 3 units/I) were stored at -25°C until use.
Immunometric assays
Microtitre plates were coated with F(ab x )2-fragments of the OC125 or with CA 125 overnight at 4°C in 100 μΐ coating buffer A per well. The coated wells were then washed once with washing buffer C (300 μΐ/well) and blocked with 200 μΐ buffer D per well for l h at room temperature. After three washes with buffer C, the immobilized antibody or antigen was incubated for 18 h at 4°C with 100 μΐ/well of the serum samples diluted in incubation buffer E. The plates were then washed three times with buffer C and bound murine immunoglobuliris were delected by incubation with peroxidase-labelled goat antimouse IgG or IgM (diluted 1 :2000 or 1 : 5000, with buffer E) for 2 h at 37 °C (100 μΐ/well). Following three washes, 100 μΐ of substrate solution (1 g/1 o-phenylendiamine in buffer B) was added. After incubation for 30 min at room temperature in the dark, reaction was stopped by addition of 100 μί 0.5 mol/1 H 2 SO 4 and absorbance was measured at 495 and 650 nm.
la) Determination ofanίl·OCJ25 antibodies
For determination of the concentration of anti-OC125 antibodies, 96-well Dynatech microtitre plates were coated with F(ab')2-fragments of OC125 at a concentration of 2mg/l. Sera of the immunized mice and the control samples were incubated in different concentrations (diluted 1/100, 1/200, 1/400 and 1/800) and tested for bound mouse-IgG and mouse-IgM.
Ib) Inhibition of anti-OC125 antibody binding
To determine the portion of anti-OC125 antibodies bound to the paratope of the OC125, an inhibition assay was performed. Microlitre plates were coated as described above with 200 ng/ well of F(ab')2-fragments of OC125, then incubated with 50 μΐ/ well of the serum obtained on day 68 (diluted 1/100), together with 50 μΐ purified CA"125 in rising concentrations (0.003 -30000 χ 10 3 units/1) overnight at 4°C. Bound anti-OC125 antibodies were detected as described and the percentage of inhibition was calculated in relation to serum incubated with 50 μΐ buffer E.
2a) Determination of anti-CA 125 antibodies
For determination of the concentration of anti-CA 125 antibodies, microtitre plates were coated with 100 μΐ/well of a solution of purified CA 125 (500 χ ΙΟ 3 units/1) at 4°C overnight, followed by incubation with 100 μΐ/weil of serum from the immunized mice, or with control samples (diluted 1/100, 1/200, 1/400,1/800) overnight at 4 °C. After washing, the plates were tested for bound mouse-IgG.
2b) Inhibition of anti-CA 125 antibody binding
For further characterization of anti-CA 125 antibodies, an inhibition assay was performed. Microtitre plates were coated as described above with 50 units/well of purified CA 125, then incubated with 50 μΐ/well of the serum samples obtained on day 68, together with 50 μΐ purified CA 125 (concentration range: 10 4 -10 S units/1) overnight at 4°C. Bound anti-CA 125 was detected as described and the percentage of inhibition was calculated in relation to sera incubated together with 50 μΐ buffer E.
Results
CA 125 purification
In the purification procedure, the specific activity was raised from 4.5 to 252.2 units/mg protein. By ammonium sulphate precipitation, large amounts of IgG and albumin were separated from fetal calf serum. Chromatography on Superose 6 resulted in additional separation of IgG, albumin and low molecular weight proteins. The preparation showed no cross-reactivity in immunoblots after isoelectric focussing.
Success of immunization
Before immunization with F(ab'):rfragments of the OC125, no anti-OC125 or anti-CA 125 antibodies could be detected (control samples one day before immunization).
After treatment with OC125 F(ab')2-fragments, increasing concentrations of anti-OC125 antibodies were detected in sera of all mice ( fig. 1) . Antibodies of the IgM type appeared immediately after the first immunization and reached a maximum after the second immunization. For antibodies of the IgG type, the increase was delayed, and a maximum occurred after the third boost ( fig. 2) . imum after the second immunization. After the third and fourth boost, the anti-CA 125 titre was stable or slightly decreased.
The binding of these antibodies to immobilized CA 125 was inhibited by soluble CA 125 in a concentration dependent manner and the inhibition was nearly complete at 100000 χ ΙΟ 3 The peroxidase-labelled goat anti-mouse-IgO (Fc-specific) did not bind to the F(ab) 2 -fragments of the monoclonal antibody OC125 MAb. Incubation of peroxidase-labelled goat anti-mouse-IgG (F c -speeific) in OC125 MAb-F(ab') 2 -coated microtitre plates yielded in an absorbance of about 0.030 at 495 nm after substrate addition, when read against similarly treated uncoated microtitre plates.
Discussion
In support of previous hypotheses (1, 5) about the activation of the idiotypic network and immunomodulation by application of monoclonal antibodies, this study demonstrates the induction of a murine anti-OC125 and anti-CA 125 response by immunization with OC125 F(ab')2-fragments.
As previously described for an ovarian cancer patient »(9), we demonstrate in this study that repeated immunization with this murine antibody induces the formation of anti-OC125 antibodies in mice. The binding of these antibodies to OC125 F(ab') 2 -fragments was inhibited by the CA 125 antigen, suggesting that the responsible IgG are anti-idiotypic antibodies binding either at or near the paratope of the OC125 (Ab2ß or ). After immunization with murine antibodies, humans form anti-isotypic and anti-allotypic antibodies to antigenie determinants common on mouse immunoglobulins, as well as highly specific anti-idiotypic antibodies (13 -17) . In mice, however, antibodies against idiotypic and allotypic determinants can be expected. However, the fact that binding of anti-OC125 antibodies was completely inhibited by CA 125 indicates that there were no detectable concentrations of anti-allotypic antibodies. Also, antiidiotypic antibodies,-binding to idiotypes which are not inhibited by the antigen, as demonstrated in previous studies (18, 19) , obviously are not formed. This is in concordance with our results in humans, where binding of anti-idiotypic antibodies to OC125 was inhibited completely by CA 125 (9) . On the other hand, the CA 125 molecule by virtue of its large size (M r about 200 000) may inhibit binding to many idiotopes by steric hindrance, so that it is difficult to determine whether the Ab2 is Ab2ß or .
The inhibition curves of the five mouse sera showed certain differences, which might be due to a set of anti-idiotypic antibodies with different affinities.
According to the network hypothesis, anti-idiotypic antibodies of the Ab2ß type imitate the original antigen of the Abl and can serve as an internal image of the nominal antigen. This internal image possibly activates the idiotypic network by producing antianti-idiotypic antibodies (Ab3), which bind to the binding sites of both Ab2ß and the original antigen. In the animal model, murine antibodies against the tumour-associated antigen CA 125 were also detected. Concerning the Ab2 detection in sera of immunized mice, only anti-idiotypic antibodies with higher affinity to the OC125 than to the Ab3 are detectable.
Anti-idiotypic antibodies were found in tumour patients after treatment with monoclonal antibodies of different specificities (8, 9, 18, 20, 21) . The induction of anti-idiotype Ab2 is correlated with a delayed clinical response in these patients (6, 8, 11, 22) .
Our first results in patients with advanced ovarian carcinomas indicate that, in spite of the same surgical and chemotherapeutic treatment, the survival rate is improved after vaccination with antibody-fragments of the OC125 during repeated immunoscintigraphy (10, 11) . In these patients showing clinical benefit, the appearance of anti-idiotypic antibodies was demonstrated (9); furthermore, we found an induction of a tumour-specific cellular immunity against autologous tumour tissue, parallel to the production of antiidiotypic antibodies (23) .
The present investigation demonstrates the activation of the idiotypic network from Abl to Ab2 and at least the production of Ab3. The interpretation of the immune system as an idiotypic network provides a basis for inducing an alteration in the immuriological response of a tumour patient, which specifically breaks the existing antitumour tolerance, resulting in a beneficial clinical response. Furthermore, this system offers the possibility of immunization against tumour-associated antigens without using the original antigen.
